KLKB1 and hereditary angioedema: CRISPR/Cas and base editing machinery can already be delivered via lipid nanoparticles to hepatocytes to delete specific genes (e.g., KLKB1 for hereditary angioedema and PCSK9 for familial hypercholesterolaemia), with promising results in clinical trials [46,47].